Zynerba Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.87 Insider Own2.70% Shs Outstand47.06M Perf Week-13.11%
Market Cap20.90M Forward P/E- EPS next Y-0.67 Insider Trans-6.52% Shs Float44.05M Perf Month-11.60%
Income-35.80M PEG- EPS next Q-0.18 Inst Own23.70% Short Float / Ratio0.54% / 0.73 Perf Quarter-18.32%
Sales- P/S- EPS this Y50.00% Inst Trans-0.89% Short Interest0.24M Perf Half Y-51.98%
Book/sh1.21 P/B0.35 EPS next Y18.30% ROA-50.30% Target Price5.44 Perf Year-80.17%
Cash/sh1.12 P/C0.37 EPS next 5Y- ROE-58.20% 52W Range0.39 - 2.28 Perf YTD-22.94%
Dividend- P/FCF- EPS past 5Y18.10% ROI- 52W High-82.09% Beta1.74
Dividend %- Quick Ratio6.40 Sales past 5Y- Gross Margin- 52W Low4.72% ATR0.04
Employees28 Current Ratio6.40 Sales Q/Q- Oper. Margin- RSI (14)39.31 Volatility12.66% 9.89%
OptionableYes Debt/Eq0.00 EPS Q/Q24.90% Profit Margin- Rel Volume0.34 Prev Close0.42
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume325.73K Price0.41
Recom1.70 SMA20-8.11% SMA50-22.64% SMA200-48.90% Volume46,639 Change-2.76%
Dec-21-20Reiterated H.C. Wainwright Buy $12 → $9
Jul-01-20Downgrade Needham Buy → Hold
Dec-31-19Resumed ROTH Capital Buy $12
Oct-21-19Initiated Needham Buy $18
Apr-22-19Resumed Canaccord Genuity Buy
Feb-01-18Resumed H.C. Wainwright Buy $23
Jan-29-18Initiated Ladenburg Thalmann Buy $25.50
Jan-26-18Initiated Seaport Global Securities Buy $16
Oct-02-17Upgrade Cantor Fitzgerald Neutral → Overweight $4 → $17
Sep-29-17Upgrade Piper Jaffray Neutral → Overweight
Show Previous Ratings
Mar-28-23 07:30AM
Mar-13-23 04:15PM
Mar-07-23 07:00AM
Mar-01-23 07:00AM
Jan-11-23 08:30AM
09:56AM Loading…
Jan-08-23 09:56AM
Dec-21-22 07:29AM
Dec-05-22 07:30AM
Nov-29-22 07:00AM
Nov-28-22 07:30AM
Nov-15-22 07:30AM
Nov-14-22 07:30AM
Nov-02-22 07:30AM
Oct-17-22 07:00AM
07:00AM Loading…
Oct-10-22 07:00AM
Oct-06-22 07:00AM
Sep-29-22 07:00AM
Sep-22-22 07:00AM
Sep-08-22 09:15AM
Sep-06-22 07:00AM
Aug-31-22 07:00AM
Aug-10-22 07:00AM
Aug-03-22 07:00AM
Aug-01-22 07:11AM
Jul-21-22 07:00AM
Jul-07-22 07:00AM
Jun-24-22 01:19PM
Jun-22-22 10:39AM
Jun-21-22 08:05PM
07:00AM Loading…
Jun-01-22 07:00AM
May-24-22 07:00AM
May-17-22 07:00AM
May-16-22 07:00AM
May-11-22 01:30PM
May-09-22 04:57PM
May-02-22 07:00AM
Apr-21-22 07:00AM
Apr-05-22 07:00AM
Mar-22-22 07:00AM
Mar-08-22 10:00AM
Mar-04-22 02:34PM
Mar-01-22 06:00AM
Feb-28-22 04:05PM
Feb-22-22 05:13AM
Feb-15-22 07:00AM
Feb-10-22 07:00AM
Jan-06-22 07:00AM
Jan-05-22 06:29AM
Jan-04-22 04:05PM
Dec-06-21 07:00AM
Nov-22-21 07:00AM
Nov-15-21 07:00AM
Oct-21-21 07:00AM
Oct-19-21 04:15PM
Oct-08-21 07:30AM
Sep-20-21 07:00AM
Sep-13-21 07:00AM
Sep-09-21 11:06AM
Sep-07-21 07:00AM
Sep-02-21 07:30AM
Aug-09-21 07:00AM
Aug-04-21 07:30AM
Aug-02-21 01:31PM
Jul-07-21 07:30AM
Jun-30-21 07:00AM
Jun-29-21 09:01AM
Jun-11-21 02:44PM
Jun-09-21 04:05PM
Jun-07-21 08:00AM
Jun-04-21 07:30AM
Jun-03-21 10:00AM
May-27-21 07:30AM
May-26-21 07:30AM
May-17-21 08:00AM
May-12-21 06:45AM
May-06-21 07:53AM
May-05-21 04:05PM
Apr-29-21 02:00PM
Apr-15-21 07:30AM
Apr-06-21 07:30AM
Mar-31-21 12:15PM
Mar-28-21 08:15AM
Mar-12-21 05:22AM
Mar-10-21 06:45AM
Mar-05-21 05:50PM
Mar-04-21 08:00AM
Feb-26-21 05:50PM
Feb-11-21 11:29AM
Feb-03-21 04:25PM
Jan-04-21 07:30AM
Dec-23-20 05:30AM
Dec-17-20 08:10AM
Dec-09-20 03:49PM
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Parker Albert PChief Legal OfficerFeb 15Sale0.543,1731,719227,018Feb 17 04:21 PM
ANIDO ARMANDOChairman & Chief Exec. OfficerJan 23Sale0.6035,45321,194576,235Jan 25 05:25 PM
Sebree Terri BPresidentJan 23Sale0.6024,66114,742343,204Jan 25 05:29 PM
Fickenscher James EChief Financial OfficerJan 23Sale0.6017,76910,622154,736Jan 25 05:28 PM
Rosenberger BrianVP, Commercial & Business Dev.Jan 23Sale0.6012,6637,57094,848Jan 25 05:26 PM
ANIDO ARMANDOChairman & CEOJul 19Sale1.1011,89913,089611,688Jul 20 04:05 PM
Sebree Terri BPresidentJul 19Sale1.108,2819,109367,865Jul 20 04:08 PM
Fickenscher James EChief Financial OfficerJul 19Sale1.106,0136,614172,505Jul 20 04:05 PM
Rosenberger BrianVP, Commercial & Business Dev.Jul 19Sale1.104,2894,718107,511Jul 20 04:06 PM
Butler John P.DirectorJun 14Sale1.01535433,056Jun 16 09:48 PM
KISNER DANIEL LDirectorJun 14Sale1.01404028,069Jun 16 09:53 PM
FEDERICI WILLIAM JDirectorJun 14Sale1.01404028,069Jun 16 09:52 PM
Stephenson PamelaDirectorJun 14Sale1.01404028,069Jun 16 09:51 PM
MOCH KENNETH IDirectorJun 14Sale1.01404028,069Jun 16 09:50 PM
COOPER WARREN DDirectorJun 14Sale1.01404028,069Jun 16 09:49 PM